

- a1
8. (Amended) A composition comprising:  
isolated skeletal myoblasts; and  
isolated fibroblast cells,  
wherein the composition is cultured *in vitro* a maximum of about 14 days.
9. (Amended) A composition comprising:  
isolated skeletal myoblasts; and  
isolated fibroblast cells,  
wherein the composition is cultured *in vitro* a maximum of about 7 days.
10. (Amended) A composition comprising:  
isolated skeletal myoblasts; and  
isolated fibroblast cells,  
wherein cells in the composition are permitted to double about one time *in vitro* prior to  
transplantation.
- 
- a2
12. (Amended) The composition of claim 10, wherein the cells are permitted to double  
less than about 10 times *in vitro* prior to transplantation.
- 
- a3
14. (Amended) A composition comprising:  
isolated skeletal myoblasts; and  
isolated fibroblast cells,  
wherein the composition engrafts into cardiac tissue after transplantation into a subject.
- 
- a4
18. (Amended) A composition comprising:  
isolated skeletal myoblasts; and  
isolated fibroblast cells,  
wherein the skeletal myoblast cells are engineered to express a GATA transcription factor.
- 

### Remarks

Applicant thanks the Examiner for her careful review of the case, and accepts the indication of allowable subject matter for claims 6-19. Responsive to this indication, Applicant has cancelled claims 1-5 and 20-42. Applicant has also amended the remaining claims to 1) cancel claims 16 and 17, thereby obviating all rejections other than indefiniteness of "transplantable"; 2) remove the term "transplantable"; 3) correct the dependency of claim 12; and 4) incorporate the limitations of the base claim, and any intervening claims, into the allowable claims, as suggested by the Examiner. Applicant makes these amendments in order to further prosecution of the present application toward allowance, but without conceding